1. Home
  2. HG vs TNGX Comparison

HG vs TNGX Comparison

Compare HG & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hamilton Insurance Group Ltd. Class B

HG

Hamilton Insurance Group Ltd. Class B

N/A

Current Price

$38.32

Market Cap

3.8B

Sector

N/A

ML Signal

N/A

Logo Tango Therapeutics Inc.

TNGX

Tango Therapeutics Inc.

N/A

Current Price

$21.96

Market Cap

4.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HG
TNGX
Founded
2013
2014
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
4.1B
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
HG
TNGX
Price
$38.32
$21.96
Analyst Decision
Buy
Strong Buy
Analyst Count
7
13
Target Price
$39.86
★ $47.00
AVG Volume (30 Days)
404.0K
★ 3.6M
Earning Date
10-29-2026
11-09-2026
Dividend Yield
★ 5.29%
N/A
EPS Growth
★ 51.23
26.89
EPS
★ 3.54
N/A
Revenue
★ $2,905,524,000.00
$62,384,000.00
Revenue This Year
$0.13
N/A
Revenue Next Year
$2.38
N/A
P/E Ratio
$10.67
★ N/A
Revenue Growth
24.70
★ 48.29
52 Week Low
$25.53
$8.30
52 Week High
$39.50
$34.39

Technical Indicators

Market Signals
Indicator
HG
TNGX
Relative Strength Index (RSI) 61.13 44.62
Support Level $33.53 $20.49
Resistance Level N/A $22.01
Average True Range (ATR) 0.99 1.92
MACD 0.01 -0.15
Stochastic Oscillator 71.43 18.52

Price Performance

Historical Comparison
HG
TNGX

About HG Hamilton Insurance Group Ltd. Class B

Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select, and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Share on Social Networks: